

Prof. Ali Yagız ÜRESİN

Personal Information

Office Phone: [+90 212 414 2000](tel:+902124142000) Extension: 32412

Office Phone: [+90 212 414 2240](tel:+902124142240) Extension: 32412

Fax Phone: [+90 212 414 2052](tel:+902124142052)

Email: yagiz@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/yagiz/>

Address: İstanbul Tıp Fakültesi Temel Bilimler Binası Tıbbi Farmakoloji Anabilim Dalı Çapa-Fatih/İSTANBUL

International Researcher IDs

Publons / Web Of Science ResearcherID: AAT-5676-2020

Yoksis Researcher ID: 121493

Education Information

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, Farmakoloji Ve Klinik Farmakoloji Anabilim Dalı, Turkey 1987 - 1990

Undergraduate, Istanbul University, Istanbul Medical Faculty, Tıp, Turkey 1980 - 1986

Foreign Languages

German, C1 Advanced

Dissertations

Expertise In Medicine, Opioid nitelikte stres uyaranlarının ouabain tarafından oluşturulan aritmilere ve serum endojen digoksin benzeri madde düzeyine etkileri , Istanbul University, Farmakoloji, İstanbul Üniversitesi İstanbul Tıp Fakültesi farmakoloji Anabilim Dalı, 1990

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Medicine Education, Internal Medicine Sciences, Pharmacology and Clinical Pharmacology, Cardiovascular

Academic Titles / Tasks

Professor, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 2004 - Continues

Associate Professor, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 1998 - 2004

Assistant Professor, Istanbul University, Istanbul Medical Faculty, Division of Medical Sciences , 1993 - 1998

Academic and Administrative Experience

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Evaluation of Stress Response in Middle-Aged Male Diabetic Hypertensive Patients**
Alloqi Tahirbegolli I, Tahirbegolli B., Şen S., Sayın B., Kaşkal M., Üresin A. Y.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol.108, no.9, pp.2307-2314, 2023 (SCI-Expanded)
- II. **Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study**
Voss E. A., Shoaibi A., Yin Hui Lai L., Blacketer C., Alshammari T., Makadia R., Haynes K., Sena A. G., Rao G., van Sandijk S., et al.
ECLINICALMEDICINE, vol.58, 2023 (SCI-Expanded)
- III. **Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis**
ŞEN S., KARAHAN E., BÜYÜKULAŞ C., POLAT Y. O., ÜRESİN A. Y.
ANATOLIAN JOURNAL OF CARDIOLOGY, vol.25, no.11, pp.753-762, 2021 (SCI-Expanded)
- IV. **Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP/TIME-to-START**
Bahat G., İlhan B., Erdogan T., Halil M., Savas S., Ulger Z., Akyuz F., Bilge A., Cakir S., Demirkan K., et al.
EUROPEAN GERIATRIC MEDICINE, vol.11, no.3, pp.491-498, 2020 (SCI-Expanded)
- V. **Chrono-pharmacological effects of antihypertensive drugs**
Şen S., Kaşkal M., Uresin Y.
EUROPEAN HEART JOURNAL, vol.41, no.16, pp.1601, 2020 (SCI-Expanded)
- VI. **Legal and ethical framework for global health information and biospecimen exchange-an international perspective**
Bernasconi L., Sen S., Angerame L., Balyegisawa A. P., Hui D. H. Y., Hotter M., Hsu C. Y., Ito T., Jorger F., Krassnitzer W., et al.
BMC MEDICAL ETHICS, vol.21, no.1, 2020 (SCI-Expanded)
- VII. **Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy**
Sen S., Demir M., Yigit Z., Uresin A. Y.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, vol.23, no.4, pp.318-328, 2018 (SCI-Expanded)
- VIII. **Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients**
Ridker P. M., Revkin J., Amarenco P., Brunell R., Curto M., Civeira F., Flather M., Glynn R. J., Gregoire J., Jukema J. W., et al.
NEW ENGLAND JOURNAL OF MEDICINE, vol.376, no.16, pp.1527-1539, 2017 (SCI-Expanded)
- IX. **EVALUATING THE RELATIONSHIP OF BLOOD PRESSURE, PLASMA ANGIOTENSIN PEPTIDES AND ALDOSTERONE WITH COGNITIVE FUNCTIONS IN PATIENTS WITH HYPERTENSION**
Sen S., Gurel N., Ufuktepe B., Ozunal Z. G., Buyuklu C., Uresin Y.
EXCLI JOURNAL, vol.16, pp.245-255, 2017 (SCI-Expanded)
- X. **Cost of heart failure management in Turkey: results of a Delphi Panel**
Aras D., Aydogdu S., Bozkurt E., ÇAVUŞOĞLU Y., Eren M., EROL Ç., Gulec S., Kizilirmak P., Ongen Z., Ozdemir O., et al.
ANATOLIAN JOURNAL OF CARDIOLOGY, vol.16, no.8, pp.554-562, 2016 (SCI-Expanded)
- XI. **Effects of Blood Pressure Lowering With Different Antihypertensive Agents on Cognitive Function and Plasma Brain-derived Neurotrophic Factor Levels: A Comparative Study**
Demir M., Gurol A. O., Ozyigit R. T., Uresin A. Y.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol.67, no.6, pp.538-543, 2016 (SCI-Expanded)
- XII. **Economic Impact of Clinical Research to Research Centers and Opportunity Cost for the Reimbursement System in Turkey**
Koçkaya G., DEMİR M., Koçkaya P. D., Tatar M., ÜRESİN A. Y.

HEALTH, vol.7, no.9, pp.1124-1133, 2015 (SSCI)

XIII. Hypertension and valsartan

Kizilirmak P., Uresin A. Y.

ANATOLIAN JOURNAL OF CARDIOLOGY, vol.14, 2014 (SCI-Expanded)

XIV. ECONOMIC IMPACT OF CLINICAL RESEARCHES TO THE RESEARCH CENTERS AND REIMBURSEMENT SYSTEMS IN TURKEY

Kockaya G., Kockaya D. P., Demir M., Uresin A. Y.

VALUE IN HEALTH, vol.17, no.7, 2014 (SCI-Expanded)

XV. Experience in Alzheimer's Disease Clinical Trials in Turkey

Uresin Y., Ilbars H., Gurvit I. H., Emre M.

GLOBAL CLINICAL TRIALS FOR ALZHEIMER'S DISEASE: DESIGN, IMPLEMENTATION, AND STANDARDIZATION, pp.277-288, 2014 (SCI-Expanded)

XVI. RENIN INHIBITORS IN DIABETES AND HYPERTENSION: AN UPDATE

Sen S., Ufuktepe B., Ozunal Z. G., Uresin Y.

EXCLI JOURNAL, vol.13, pp.1111-1119, 2014 (SCI-Expanded)

XVII. The Efficacy and Safety of Triple vs Dual Combination of Angiotensin II Receptor Blocker and Calcium Channel Blocker and Diuretic: A Systematic Review and Meta-Analysis

Kizilirmak P., Berktaş M., Uresin Y., YILDIZ O. B.

JOURNAL OF CLINICAL HYPERTENSION, vol.15, no.3, pp.193-200, 2013 (SCI-Expanded)

XVIII. ECONOMIC EFFECT OF CLINICAL TRIALS FOR TURKEY

Kockaya G., Demir M., Uresin A. Y.

VALUE IN HEALTH, vol.15, no.7, 2012 (SCI-Expanded)

XIX. Comparison of immediate release and extended release formulations in therapy

Uresin Y., Baran E.

KLINIK PSIKOFARMAKOLOJİ BÜLTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, 2011 (SCI-Expanded)

XX. Direct Inhibition of Renin

Uresin Y., Ozunal Z. G.

TRAKYA UNIVERSİTESİ TIP FAKÜLTESİ DERGİSİ, vol.27, pp.82-84, 2010 (SCI-Expanded)

XXI. Potential Adjuvant Effects of Nigella sativa Seeds to Improve Specific Immunotherapy in Allergic Rhinitis Patients

Isik H., Cevikbas A., Gurer U. S., Kiran B., Uresin Y., RAYAMAN P., RAYAMAN E., GÜRBÜZ B., Buyukozturk S.

MEDICAL PRINCIPLES AND PRACTICE, vol.19, no.3, pp.206-211, 2010 (SCI-Expanded)

XXII. EFFECT OF RENIN-ANGIOTENSIN SYSTEM BLOCKADE ON LEPTIN, ADIPONECTIN, RESISTIN AND INSULIN LEVELS IN PATIENTS WITH METABOLIC SYNDROME

Erbas B., Sidan R., Sabirli S., Gurol A. O., Midi I., Uresin Y.

ATHEROSCLEROSIS SUPPLEMENTS, vol.9, no.1, pp.129, 2008 (SCI-Expanded)

XXIII. EEG AS A POSSIBLE DIAGNOSTIC TOOL FOR MILD COGNITIVE IMPAIRMENT IN ATHEROSCLEROSIS

Uresin Y., Sabirli S., Ozunal Z. G., Karamursel S.

ATHEROSCLEROSIS SUPPLEMENTS, vol.9, no.1, pp.155, 2008 (SCI-Expanded)

XXIV. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

Uresin Y., Taylor A. A., Kilo C., Schpe D., Santonastaso M., Ibram G., Tang H., Satlin A.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.8, no.4, pp.190-198, 2007 (SCI-Expanded)

XXV. Aliskiren, the future of renin-angiotensin system blockade?

Uresin Y., Bozkurt M. M., Sabirli S., Ozunal Z.

Expert Review of Cardiovascular Therapy, vol.5, no.5, pp.835-849, 2007 (SCI-Expanded)

XXVI. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study)

Ilerigelen B., Uresin Y., San M., Kueltesay H., Gueneri S., Serdar O. A., Guelec S., Pencedemir H.

CURRENT MEDICAL RESEARCH AND OPINION, vol.23, no.5, pp.1093-1102, 2007 (SCI-Expanded)

- XXVII. **Effects of valsartan on stress-induced changes of serum vascular endothelial growth factor and nitric oxide in mice**
Erbas B., Uresin Y., Ozek M., Dogru-Abbasoglu S.
INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.116, no.5, pp.601-611, 2006 (SCI-Expanded)
- XXVIII. **Influence of polymerization method, curing process, and length of time of storage in water on the residual methyl methacrylate content in dental acrylic resins**
Bayraktar G., Guvener B., Bural C., Uresin Y.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, no.2, pp.340-345, 2006 (SCI-Expanded)
- XXIX. **Effects of nitrendipine on reference and working memory of rats in three-panel runway**
Celik P., Uresin Y., Tonyali H.
PHARMACOLOGICAL RESEARCH, vol.50, no.3, pp.367-370, 2004 (SCI-Expanded)
- XXX. **Alpha rhythm of the EEG modulates visual detection performance in humans**
Ergenoglu T., Demiralp T., Bayraktaroglu Z., Ergen M., Beydagi H., Uresin Y.
COGNITIVE BRAIN RESEARCH, vol.20, no.3, pp.376-383, 2004 (SCI-Expanded)
- XXXI. **Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress**
URESIN Y., ERBAS B., OZEK M., OZKOK E., Gurol A. O.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.5, no.2, pp.93-96, 2004 (SCI-Expanded)
- XXXII. **The effects of losartan and immobilization stress on heart rate variability and plasma corticosterone levels in rats**
Uresin A. Y., Tonyali H., Karamursel S.
INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol.114, no.3, pp.365-379, 2004 (SCI-Expanded)
- XXXIII. **Losartan may prevent the elevation of plasma glucose levels induced by chronic stress**
Uresin Y., Erbas B., Ozek M.
POLISH JOURNAL OF PHARMACOLOGY, vol.56, no.2, pp.271-273, 2004 (SCI-Expanded)
- XXXIV. **Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia, tolerance and dependence in mice**
Ozek M., Uresin Y., Gungor M.
LIFE SCIENCES, vol.72, no.17, pp.1943-1951, 2003 (SCI-Expanded)
- XXXV. **A model of pharmacology education: The experience of Istanbul Medical Faculty**
Eroglu L., Uresin Y.
JOURNAL OF CLINICAL PHARMACOLOGY, vol.43, no.3, pp.237-242, 2003 (SCI-Expanded)
- XXXVI. **Protective effects of dextromethorphan and tizanidine on ouabain-induced arrhythmias**
Uresin Y., Ozek M., Sevgi S.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol.24, no.7, pp.421-423, 2002 (SCI-Expanded)
- XXXVII. **Changes in HDL-cholesterol levels in response to stress and losartan**
Uresin Y., Sevgi S., Ozek M., Guvener B., Canberk A.
ATHEROSCLEROSIS, vol.146, 1999 (SCI-Expanded)
- XXXVIII. **Effects of slow cortical potential shifts on P300 response**
Ergenoglu T., Demiralp T., Beydagi H., Karamursel S., Devrim M., Ermutlu N.
INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, vol.30, pp.239, 1998 (SCI-Expanded)
- XXXIX. **Electrophysiological effects of reversible MAO-A inhibitors Moclobemid in healthy volunteers**
Ermutlu N., Uresin Y., Demiralp T.
JOURNAL OF PSYCHOPHYSIOLOGY, vol.12, no.1, pp.98, 1998 (SCI-Expanded)
- XL. **Protective role of immobilization on ouabain-induced arrhythmias**
Uresin Y., Eroglu L., Yildiran G., Guvener B., Ozkok E.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol.19, no.9, pp.633-636, 1997 (SCI-Expanded)
- XLI. **Optimizing the absorption of valsopodar, a P-glycoprotein modulator .1. Selecting an oral formulation**

and exploring its clinical pharmacokinetics/dynamics

Mueller E., Kovarik J., Uresin Y., PreisigFluckiger S., Hensel S., Lucker P., Holt B.

JOURNAL OF CLINICAL PHARMACOLOGY, vol.37, no.11, pp.1001-1008, 1997 (SCI-Expanded)

XLII. Effects of opioid-type stressors on serum digoxin-like immunoreactivity in rats

Uresin Y., Eroglu L., Yildiran G.

METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol.18, no.9, pp.569-571, 1996 (SCI-Expanded)

XLIII. MORPHINE AND NALOXONE ACT SIMILARLY ON GLUTAMATE-CAUSED GUINEA-PIG ILEUM CONTRACTION

KOYUNCUOGLU H., URESIN Y., ESIN Y., ARICIOGLU F.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol.43, no.2, pp.479-482, 1992 (SCI-Expanded)

XLIV. EFFECTS OF TIZANIDINE ON MORPHINE PHYSICAL-DEPENDENCE - ATTENUATION AND INTENSIFICATION

KOYUNCUOGLU H., ARICIOGLU F., URESIN Y., DIZDAR Y., ESIN Y.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol.42, no.4, pp.693-698, 1992 (SCI-Expanded)

Articles Published in Other Journals

I. Evaluation of clinical trials of the plants, which have ethnobotanical uses for skin disorders in Turkey: a review

Alan Z., Özgüldü H., Erdal M. S., Yaman Bucak A., Üresin A. Y., Akalın Uruşak E.

Clinical Phytoscience, vol.79, no.7, pp.1-29, 2021 (Peer-Reviewed Journal)

II. COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?

Sen S., Uresin A. Y.

TURK KARDIYOLOJİ DERNEĞİ ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.48, no.7, pp.631-634, 2020 (Peer-Reviewed Journal)

III. Traditional Chinese medicine practices used in COVID-19 (Sars-cov 2/Coronavirus-19) treatment in clinic and their effects on the cardiovascular system COVID-19 (Sars-cov 2/Koronavirüs-19) tedavisinde klinikte kullanılan geleneksel Çin tıbbi bitkileri ve kardiyovasküler sisteme etkileri

Akalın E., Ekici M., Alan Z., Elekli Özbir E., Bucak Yaman A., Aobulaike N., Üresin A. Y.

Türk Kardioloji Derneği Arsivi, vol.48, no.4, pp.410-424, 2020 (ESCI)

IV. Renin-angiotensin system in stress response and the effect of chronic exercise in healthy volunteers

Ozunal Z. G., Sabırlı S., Şen S., Karamürsel S., Ömer B., Yıldız S., Üresin A. Y.

Annals of Medical Research, vol.27, no.4, pp.988-992, 2020 (Peer-Reviewed Journal)

V. Evaluation of statin use on LDL cholesterol levels in Turkey: A systematic review

Kızılırmak P., Ongen Z., Kayıkcıoğlu M., Tokgozoglu L.

TURK KARDIYOLOJİ DERNEĞİ ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.48, no.2, pp.137-148, 2020 (ESCI)

VI. Dislipidemi ve Pitavastatin

ÜRESİN A. Y., ŞEN S.

Klinik Aktüel Tıp İç Hastalıkları Forumu, pp.40-46, 2018 (Non Peer-Reviewed Journal)

VII. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials

Kızılırmak P., Uresin Y., Ozdemir O., Avcı B. K., Tokgozoglu L., Ongen Z.

TURK KARDIYOLOJİ DERNEĞİ ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.45, no.1, pp.49-66, 2017 (ESCI)

VIII. Vadi Tepe Oranı mı? Yarılanma Ömrü mü?

ÜRESİN A. Y., ŞEN S.

Medilog Tıp Günlüğü Hipertansiyon Özel Sayı, no.2, pp.46-48, 2015 (Non Peer-Reviewed Journal)

IX. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials

Şen S., Sabırlı S., Özyığıt T., Uresin Y.

THERAPEUTIC ADVANCES IN CHRONIC DISEASE, vol.4, no.5, pp.232-241, 2013 (Peer-Reviewed Journal)

- X. **Pharmacological properties and clinical use of candesartan: Review Kandesartanın farmakolojik özellikleri ve klinik kullanımı**
Üresin A. Y., Şen S.
Türkiye Klinikleri Cardiovascular Sciences, vol.24, no.2, pp.134-140, 2012 (Scopus)
- XI. **The efficacy and undesired effects of high dosage zinc treatment**
Kockaya G., Ufuktepe B., Kockaya P. D., Sen S., Altunel O., Uresin Y.
Journal of Applied Pharmaceutical Science, vol.2, no.3, pp.157-159, 2012 (Scopus)
- XII. **The future of renin inhibition**
ÜRESİN A. Y., Baran E.
TURK KARDIYOLOJİ DERNEĞİ ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.37, pp.32-38, 2009 (ESCI)
- XIII. **Safety of statins**
Uresin Y., Sabirli S.
TURK KARDIYOLOJİ DERNEĞİ ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.35, pp.15-23, 2007 (ESCI)
- XIV. **Kuzularda Enrofloksasinin Biyoyararlanımı**
YILDIRIM M., ÜRESİN A. Y., DEMİREL H., (İLTER) BAKİREL T., BAKİREL U.
İSTANBUL ÜNİVERSİTESİ VETERİNER FAKÜLTESİ DERGİSİ, vol.22, no.1, pp.49-55, 1996 (Scopus)
- XV. **Endogenous digoxin like activity in patients with hyperbilirubinemia**
Tascioglu C., Azezli A., Orhan Y., Uresin Y., Ates A.
İstanbul Tıp Fakultesi Mecmuası, vol.56, no.2, pp.15-17, 1993 (Scopus)

Books & Book Chapters

- I. **Orphan Drugs**
Şen S., Üresin A. Y.
in: Rare Diseases, Uğur Özbek, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.91-95, 2021
- II. **Plant-Based Natural Compounds in Clinical Trials of COVID-19 (SARS-CoV-2) Treatment.**
Akalin Urusak E., Ekici M., Alan Z., Yaman Bucak A., Üresin A. Y.
in: Covid-19: Molecular and Clinical Approach, Bedia Çakmakoglu, Sema Sırma Ekmekçi, Umut Can Küçüksezer, Vuslat Yılmaz, Günnur Deniz, Editor, Istanbul University, İstanbul, pp.263-284, 2020

Refereed Congress / Symposium Publications in Proceedings

- I. **Türkiye'de Hipertansiyon Tedavisinde Geleneksel Olarak Kullanılan Bitkilerin Etkinlik, Güvenlik ve Etki Mekanizmalarının Değerlendirilmesi**
Ekici M., Tuncay H. O., Akalin E., Gürel N., Üresin A. Y.
XXIV. Bitkisel İlaç Hammaddeleri Toplantısı, Ankara, Turkey, 23 - 26 June 2022, pp.150-151
- II. **Hipertansiyon Hastalarında Stres Yanıtındaki Değişimlerin Kognitif Fonksiyonlara ve Kliniğe Yansımalarının Biyokimyasal ve Elektrofizyolojik Yöntemlerle Araştırılması**
Büyüklü Ç., Şen S., Gürel N., Demiralp T., Üresin A. Y.
25. Ulusal Farmakoloji Kongresi, Aydın, Turkey, 4 - 07 November 2019, pp.134
- III. **Türkiye Yaşlılarda Uygun İlaç Kullanım Kriterleri - TIME Kriterleri**
BAHAT-ÖZTÜRK G., İlhan B., Erdoğan T., Halil M., savaş S., AKYÜZ F., BİLGE A. K., ÇAKIR S., Demirkan K., ERELEL M., et al.
2. Uluslararası ve 12. Akademik Geriatri Kongresi, Antalya, Turkey, 24 - 28 April 2019, pp.1
- IV. **İyi Klinik Uygulamalar Çerçevesinde Klinik Araştırma Eğitim Değerlendirmesi: İstanbul Tıp Fakültesi**

Tıbbi ve Klinik Farmakoloji Uygulamaları (INSAC-18-1112)(ISBN: 978-605-69062-0-6)

DEMİR M., DİZDAR M. Y., BEBEK N., AKKAYA V. A., TÜKEK T., GÜRSER R. C., GÜROL A. O., SAİP P. M., ÜRESİN A. Y.
International Science and Academic Congress'18, Konya, Turkey, 8 - 09 December 2018, vol.1, pp.99-103

V. Cost of Obesity for Turkey

Kockaya G., Tatar M., Ergin G., Atikeler K., Ozmen M., Gorgun M., Coskun H., Alis H., Sahin M., Uresin Y., et al.
18th World Congress of the International-Federation-for-the-Surgery-of-Obesity-and-Metabolic-Disorders (IFSO),
İstanbul, Turkey, 28 - 31 August 2013, vol.23, pp.1143

VI. Economic Value of Obesity Surgery for Turkey

Kockaya G., Atikeler K., Ergin G., Tatar M., Ozmen M., Gorgun M., Coskun H., Alis H., Sahin M., Uresin Y., et al.
18th World Congress of the International-Federation-for-the-Surgery-of-Obesity-and-Metabolic-Disorders (IFSO),
İstanbul, Turkey, 28 - 31 August 2013, vol.23, pp.1143

VII. Operational Cost of Obesity Surgery for Turkey

Kockaya G., Ergin G., Atikeler K., Tatar M., Ozmen M., Gorgun M., Coskun H., Alis H., Sahin M., Uresin Y., et al.
18th World Congress of the International-Federation-for-the-Surgery-of-Obesity-and-Metabolic-Disorders (IFSO),
İstanbul, Turkey, 28 - 31 August 2013, vol.23, pp.1142-1143

VIII. Aliskiren monotherapy lowers blood pressure more effectively than ramipril monotherapy in patients with diabetes and grade 2 hypertension: Subgroup analysis of an 8-week, double-blind trial

Uresin Y., Taylor A. A., Kilo C., Fang H., Lukashevich V., Keefe D. L.
18th Annual Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension, Berlin, Germany, 14 - 19 June 2008, vol.26

IX. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional bp lowering when combined with ramipril in patients with diabetes and hypertension

Uresin Y., Taylor A., Kilo C., Tschöpe D., Santonastaso M., Ibram G., Fang H., Satlin A.
16th European Meeting on Hypertension, Madrid, Spain, 12 - 15 June 2006, vol.24

X. Plasma Corticosterone Levels of Rats Trained for Reference Memory Test in Three-Panel Runway

YAMANTÜRK ÇELİK A. P., TONYALI H., ÜRESİN A. Y.
Turkish Pharmacological Society, 17th. National Congress of Pharmacology, 1st Clinical Pharmacology Symposium
& Joint Meeting of The Turkish & Dutch Pharmacological Societies, Antalya, Turkey, 1 - 04 November 2003, pp.62

Supported Projects

ÜRESİN A. Y., ŞEN S., ÖZSOY A., Project Supported by Higher Education Institutions, Antihipertansif Tedavinin Plazma Kolin, Plazma Asetilkolinesteraz, Serum hsCRP Düzeyleri ve Kognitif Fonksiyonlar Üzerine Etkisinin Değerlendirilmesi, 2020 - Continues

ÜRESİN A. Y., DÜZ H., Project Supported by Higher Education Institutions, Efektif diyabet tedavisinin bilişsel fonksiyonlar hsCRP ve BNP parametreleri açısından incelenmesi, 2020 - 2023

ÜRESİN A. Y., Project Supported by Higher Education Institutions, Hipertansiyon hastalarında renin anjiotensin aldosteron sistemi parametrelerinin kognitif fonksiyonlar ile ilişkisi, 2012 - 2013

ÜRESİN A. Y., Project Supported by Higher Education Institutions, İSTANBUL TIP FAKÜLTESİ KLİNİK ARAŞTIRMALAR RAPORU, 2011 - 2013

ÜRESİN A. Y., DEMİR M., Project Supported by Higher Education Institutions, Hipertansif Hastalarda Plazma Renin Aktivitesi ve Anjiotensin II Seviyesinin, CRP ve Bir Kognitif Fonksiyon Belirteci Olan BDNF Üzerine Etkisi, 2010 - 2012

ÜRESİN A. Y., Project Supported by Higher Education Institutions, TÜRK TOPLUMUNDA BİPOLAR BOZUKLUĞU OLAN HASTALAR VE SAĞLIKLI BİREYLERDE CYP1A2 ENZİMİNİN DÖRT POLİMORFİZMİNİN SIKLIK KARŞILAŞTIRMASI, 2009 - 2012

ÜRESİN A. Y., Project Supported by Higher Education Institutions, ?Sağlıklı gönüllülerde stres yanıtının elektrofizyolojik ve biyokimyasal olarak değerlendirilmesi ve bu yanıtı egzersizin etkisinin ve renin anjiyotensin sisteminin rolünün araştırılması?, 2008 - 2011

Metrics

Publication: 71

Citation (WoS): 1173

Citation (Scopus): 1982

H-Index (WoS): 13

H-Index (Scopus): 14

Non Academic Experience

Sandoz LTD Basel İsviçre